Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677845 · ClinicalTrials.gov registry record · Phase 1
Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01677845 is a Phase 1 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 9 participants.
The verdict
NCT01677845, a Phase 1 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The aim of this study is to determine the maximum tolerated dose of hypo-fractionated radiation therapy and the toxicity of the treatment program. Eligible patients with stage T1-2c prostate cancer who sign consent will be enrolled to this phase I dose escalation trial and be treated with hypo-fractionated radiation therapy (HRT). Dose escalation will be as follows: There will be 3 cohorts consisting of 3 patients each.
Interventions
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-05 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677845
The ClinicalTrials.gov registry entry for NCT01677845 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiation is the first listed.
NCT01677845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01677845 about?
NCT01677845 is a clinical study titled "Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer". The aim of this study is to determine the maximum tolerated dose of hypo-fractionated radiation therapy and the toxicity of the treatment program. Eligible patients with stage T1-2c prostate cancer who sign consent will be enrolled to this phase I dose escalation trial and be treated with hypo-frac...
What is the current status of trial NCT01677845?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-05. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT01677845?
The interventions under investigation include: Radiation (RADIATION).
Who is sponsoring clinical trial NCT01677845?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.